Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clearmind MedicineFRA:CWY0 22 Debt-to-EBITDA is -0.01 as of Apr. 2026. GuruFocus rates FRA:CWY0 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 306 Biotechnology companies, Clearmind Medicine ranks worse than 326797.06% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Clearmind Medicine's Debt-to-EBITDA or its related term are showing as below:
FRA:CWY0'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.48 Med: -0.01 Max: -0.01
Current: -0.01
During the past 9 years, the highest Debt-to-EBITDA Ratio of Clearmind Medicine was -0.01. The lowest was -0.48. And the median was -0.01.
FRA:CWY0's Debt-to-EBITDA is ranked worse than 100% of 306
companies
in the Biotechnology industry
Industry Median: 1.255
vs FRA:CWY0: -0.01
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Clearmind Medicine Debt-to-EBITDA Related Terms
Clearmind Medicine Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Clearmind Medicine's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CWY0 vs CASIF, BIXT, ACUT: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Clearmind Medicine's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearmind Medicine Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Clearmind Medicine's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Apr. 2026) EBITDA data.
Clearmind Medicine (FRA:CWY0) has a Debt-to-EBITDA of -0.01 as of Apr. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Clearmind Medicine. According to the industry distribution chart, Clearmind Medicine ranks #999999 out of 306 companies in the Biotechnology industry.
Is Clearmind Medicine's Debt-to-EBITDA too high?
Clearmind Medicine's current Debt-to-EBITDA is -0.01. Based on the distribution chart, Clearmind Medicine ranks #999999 out of 306 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clearmind Medicine has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Clearmind Medicine's Debt-to-EBITDA compare to CASIF and BIXT?
According to the Biotechnology industry distribution chart, Clearmind Medicine ranks #999999 out of 306 companies for Debt-to-EBITDA. This places Clearmind Medicine in the lower half of its industry. The industry median Debt-to-EBITDA is 1.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.26, based on 306 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Clearmind Medicine. For the Biotechnology industry, the median Debt-to-EBITDA is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearmind Medicine's current Debt-to-EBITDA is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearmind Medicine stock overvalued right now?
Clearmind Medicine (FRA:CWY0) has a current Debt-to-EBITDA of -0.01. The current Debt-to-EBITDA is -0.01. Clearmind Medicine's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Clearmind Medicine (FRA:CWY0), the current Debt-to-EBITDA is -0.01 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
22GF Score
Get the complete analysis for FRA:CWY0
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CWY0 has been successfully added to your 
